Antibodies to breast specific gene 1

Details Antibodies to breast specific gene 1 Antibodies to breast specific gene 1

2006-07-04

2006-07-04

Siew, Jeffrey (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C435S007100

Reexamination Certificate

active

07071309

ABSTRACT:
Human breast specific gene polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides or polypeptides as a diagnostic marker for breast cancer and as an agent to determine if breast cancer has metastasized. Also disclosed are antibodies specific to the breast specific gene polypeptides which may be used to target cancer cells and be used as part of a breast cancer vaccine. Methods of screening for antagonists for the polypeptide and therapeutic uses thereof are also disclosed.

REFERENCES:
patent: 5525501 (1996-06-01), Tokuyama
patent: 0 908 727 (1999-04-01), None
Bowie et al, Science, 1990, 247:1306-1310.
Herbert et al, The Dictionary of Immunology, Academic Press, 3rd Edition, London, 1985, pp. 58-59.
Ahn et al., “The structural and functional diversity of dystrophin,” Nature Genetics 3(4):283-291 (1993).
Albert, B. (ed.). Molecular Biology of the Cell, 3rd Edition, p. 403. 1996.
Allred et al., “HER-2
eu in Node-Negative Breast Cancer: Prognostic Significance of Overexpression Influenced by the Presence of In Situ Carcinoma,” J. Clin. Oncol. 10(4):599-605 (1992).
Angerer et al., “In situ hybridization to cellular RNA with radiolabelled RNA probes,” in: In situ hybridization: a practical approach, Wilkinson, D.G., ed., IRL Press at Oxford University Press, Oxford and New York; pp. 15-32 (1992).
Bergh et al., “Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy,” Nature Med. 1(10):1029-1034 (1995).
BIO Report. “Critical Synergy: The Biotechnology Industry and Intellectual Property Protection”, pp. 75, 100-107; Oct. 17, 1994.
Bork et al., “Powers and pitfalls in sequence analysis,” Genome Research 10:398-400 (2000).
Branch, A. “A hitchhiker's guide to antisense and nonantisense biochemical pathways,”, Hepatology 24:1517-1529 (1996).
Broaddus et al., “Strategies for the design and delivery of antisense oligonucleotides in central nervous system”, Methods in Enzymology 314:121-135 (2000).
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic acitivies of heparin-binding growth factgor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,” J. Cellular Biology, vol. 111 (1990).
Cawthon et al., “cDNA sequence and genomic structure of EV12B, a gene lying within an intron of theneurofibromatosis Type 1 gene,” Genomics 9(3):446-460 (1991).
Chen et al., “Differential expression human tissue factor in normal mammary epithelial cells and in carcinomas,” Mol. Med. 1(2):153-160 (1995).
Donohue et al., “Human Hydroxyindole-O-Methyltransferase: presence of LINE-1 fragment in a cDNA clone and pineal mRNA,” DNA and Cell Biology 12:715-727, Mary Ann Liebert, Inc. Publishers (1993).
Elledge et al., “The role and prognostic significance of p53 gene alterations in breast cancer,” Breast Cancer Res. Treatment 27(1/2):95-102 (1993).
Ernster et al., “Incidence of and treatment for ductal carcinoma in situ of the breast,” JAMA 275(12):913-918 (1996).
Ferno et al., “Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer,” Eur. J. Cancer 30A(14):2042-2048 (1994).
Foekens et al., “Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer,” J. Natl. Cancer Inst. 87(10):751-756 (1995).
Fritsch et al., “A soluble immunoglobulin variable domain without a disulfide bridge . . . ”, Biol. Chem. Hoppe-Seyler, vol. 375:363-356 (1994).
Futreal et al., “BRCA1 mutations in primary breast and ovarian carcinomas,” Science 266:120-122 (1994).
Gasparini et al., “Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients,” J. Natl. Cancer Inst. 85(15):1206-1219 (1993).
Gasparini et al., Erraturn: “Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients,” J. Natl. Cancer Inst. 85(19):1605 (1993).
Geneseq Accession No. AAQ61427, “Human brain Expressed Sequence Tag EST01420”, released Mar. 16, 1994.
GENBANK Accession No. H11372, “ym13a05.s1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:47522 3′ similar to SP:S21265 S21265; Acetylserotonin N-Methyltransferase;, mRNA sequence,” released Jun. 26, 1995.
GENBANK Accession No. M79265, “EST01420 Whole Brain, Clontech mRNA, Ruben Moreno Homo sapiens cDNA clone HRBAA27, mRNA sequence,” released May 26, 1992.
GENBANK Accession No. M83779, “Homo sapiens (clone 179 or 217) hydroxyindole-O-methyltransferase (HIOMT) mRNA, complete cds.” (1993).
Goldhirsch et al., “Meeting highlights: International consensus panel on the treatment of primary breast cancer,” J. Natl. Cancer Inst. 87(19):1441-1445 (1995).
Gusterson et al., “Prognostic importance of c-erbB-2 expression in breast cancer,” J. Clin. Oncol. 10(7):1049-1056 (1992).
Harris et al., “Polycystic kidney disease 1: Identification and analysis of the primary defect,” J. Am. Soc. Nephrology 6:1125-1133 (1995).
Harris et al., “Breast cancer angiogenesis: therapy target and prognostic factor,” Eur. Cancer 31A(5):831-832 (1995).
Hayes, D.F. “Tumor markers for breast cancer current utilities and future prospects,” Hematology—Oncology Clinics of North America, W.B. Saunders, ed. 8(3):485-506 (1994).
Ji et al., “Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing,” Cancer Research 57(4):759-764 (1997).
Kim et al., “Restoring allosterism with compensatory mutations in hemoglobin,” PNAS 91:11547-11551 (1994).
Klijn et al., “Prognostic factors and response to therapy in breast cancer,” Cancer Surveys 18:165-198 (1993).
Lavedan et al., “Identification, localization and characterization of the human gamma-synuclein gein,” Human Genetics 103(1):106-112 (1998).
Lazar et al., “Transforming growth factor alpha: Mutation of aspartic acid 47 and leuine 48 results in different biological activities,” Molecular and Cellular Biology 8:1247-1252 (1988).
Liang et al., “Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells,” Cancer Res. 52(24):6966-6968 (1992).
Lu et al., “Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences”, Oncogene 20(37):5173-5185 (2001).
Manning et al., “Differential expession of oestrogen regulated genes in breast cancer,” Acta Oncologica 34(5):641-646 (1995). Presented at the 5th Scandinavian Breast Cancer Symposium, Reykjavik, Iceland, 1994.
Miki et al., “A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1,” Science 266:66-71 (1994).
Matthews et al., Biochemistry, 2nd ed., The Benjamin/Cummings Publishing Co., Inc., Menlo Park, CA; pp. 165-171 (1996).
Matthews, B., “Genetic and Structural analysis of the protein stability problem, ” In Perspectives in Biochemistry, vol. 1, pp. 6-9 (1989).
Porter-Jordan et al., “Overview of the biologic markers of breast cancer,” Hematol.. Oncol. Clin. North Am. 8(1):73-100 (1994).
Sager et al., “Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene,” FASEB J. 7(10):964-970 (1993).
Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd Edition, 198

Affiliated with

Also associated with

Rating

Antibodies to breast specific gene 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to breast specific gene 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to breast specific gene 1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3569955